Clinical Trial Update: Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy [Phase 2]

View source ↗

Summary

A Phase 2 study assessing TAR-0520 Gel for prevention of taxane-induced peripheral neuropathy, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Peripheral Neuropathy

Drugs mentioned

• TAR-0520 Gel (TAR-0520)

Snippet

Sponsor: Tarian Pharma | Conditions: Chemotherapy Induced Peripheral Neuropathy | Phase 2 | Status: NOT_YET_RECRUITING